ABSTRACT
An ever-increasing number of pharmaceutical, flavor and fragrance, animal health, polymer, and agrochemical products rely on the availability of enantiomerically pure building blocks.
More than 50% of the world’s top-selling drugs are single enantiomers,
and it has been estimated that up to 80% of all drugs currently entering development are chiral and will be marketed as single enantiomer entities.
